AstraZeneca sees sales hit by copycats

Philip Waller
April 2015
Daily Mail;4/25/2015, p101
ASTRAZENECA admitted yesterday its sales had been hit by copycat products as it beat off an investor rebellion over boardroom pay. The firm, which has been battling competition from generic versions of its drugs as patents expire, said first quarter sales fell 6pc to $6.1bn while operating profits dipped 8pc to $1.8bn.


Related Articles

  • Pozen, AstraZeneca Starting Phase III Program In Arthritis. Osborne, Randall // BioWorld Today;9/10/2007, Vol. 18 Issue 175, p1 

    The article focuses on the research and development deal between London, England-based AstraZeneca PLC and Chapel Hill, North Carolina-based Pozen Inc. The companies have launched Phase III trials of the arthritis compound, PN 400. Under the development deal, AstraZeneca will provide Pozen with...

  • $100 Mil. Pharmaceutical Media Business in Play. Feuer, Jack // Adweek Midwest Edition;08/28/2000, Vol. 41 Issue 35, p3 

    Reports on the media buying consolidation planned by prescription-drug marketer AstraZeneca Pharmaceuticals. Estimated value of the combined advertising account; Drugs marketed by AstraZeneca; Sales of AstraZeneca in the first half of 2000.

  • Q2 sales for 2004 indicate robust market for some.  // PharmacoEconomics & Outcomes News;8/14/2004, Issue 459, p15 

    Reports on the increase in pharmaceutical sales of companies for the second quarter of 2004. AstraZeneca; Serono; Novartis.

  • Amgen Sells Biotech Plant to AstraZeneca.  // Chain Drug Review;9/28/2015, Vol. 37 Issue 15, p100 

    The article reports on the sale of pharmaceutical firm Amgen Inc.'s biotechnology facility to AstraZeneca PLC.

  • ASTRAZENECA ON THE WARPATH.  // Daily Mail;3/14/2012, p73 

    DRUGS giant AstraZeneca has filed a lawsuit against American regulators over their refusal to delay approval for a copy-cat version of its top-drawer anti-psychotic treatment Seroquel.

  • Pharma giants fail drugs test. Roger Baird // Daily Mail;8/9/2012, p72 

    BOTH AstraZeneca and its smaller partner BTG took a hit in the markets after announcing the failure of a key drug they were jointly testing.

  • AstraZeneca predicts top-tier earnings.  // Medical Marketing & Media;Nov2003, Vol. 38 Issue 11, p10 

    Focuses on the optimism of pharmaceutical company AstraZeneca on achievement of sales goals in the U.S. Result of the annual business review; Sales of new drugs.

  • Glaxo rises after Morgan tip that it's the pharma to follow. Oscar Williams- Grut // Evening Standard;5/15/2014, p53 

    WHILE all eyes have been on Astra-Zeneca and Pfizer, analysts at Morgan Stanley have been taking a look at GLAXOSMITHKLINE — and they like what they see.

  • Astra hurt by copy-cats.  // Daily Mail;7/27/2012, p74 

    DRUGS giant AstraZeneca warned that competition from cheaper generic drugs as well as economic uncertainty continued to eat into sales.

  • Royal robbery. ALEX BRUMMER // Daily Mail;5/14/2014, p57 

    AS if Vince Cable did not have enough on his plate with the Astra-Zeneca bid, the share sale of the Royal Mail continues to bite back.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics